STRADB

STRADB (PAPK/ILPIP) is a Ste20/germinal center kinase (GCK)-related kinase that couples stress signaling to cytoskeletal remodeling and cell survival (PMID:12574163). It forms a complex with LKB1 (Par-4) and Mo25, driving relocalization of LKB1 from the nucleus to the cytoplasm and tight junctions (PMID:14676191). STRADB is activated by hydrogen peroxide and its expression rises following growth factor withdrawal, after which it activates the stress kinases JNK1 and ERK6/p38γ; its catalytic activity is required for ERK6/p38γ activation but dispensable for JNK1 activation (PMID:12574163). Independently, STRADB interacts with XIAP and co-precipitates with TAK1 and TRAF6, strongly enhancing XIAP-mediated activation of JNK1/2/3 through a TAK1-dependent pathway and potentiating XIAP anti-apoptotic activity without altering caspase inhibition (PMID:12048196). Consistent with these signaling outputs, kinase-active STRADB induces cytoskeletal changes and confers resistance to apoptosis triggered by serum withdrawal (PMID:12574163).

1. 2002 Medium

   Established STRADB as a pro-survival adaptor by linking it physically and functionally to the XIAP–TAK1–TRAF6 anti-apoptotic axis, answering how it might bias cells toward survival.

   Evidence Yeast two-hybrid, reciprocal co-immunoprecipitation, JNK reporter assays, dominant-negative TAK1 epistasis, and apoptosis assays in cultured cells

   PMID:12048196

   Open questions at the time

   • Does not define the direct binding interface or whether STRADB's catalytic activity is required for XIAP/TAK1-mediated JNK activation
   • In vivo physiological relevance of the XIAP–STRADB interaction not established
   • Mechanism by which it potentiates XIAP without altering caspase inhibition unresolved
2. 2003 High

   Defined STRADB as a GCK-related kinase activated by oxidative stress and induced upon growth factor withdrawal, connecting its catalytic activity to stress-kinase signaling and survival phenotypes.

   Evidence In vitro kinase assay with H2O2 stimulation, inducible stable transfection, kinase-dead mutagenesis, cytoskeletal imaging, and apoptosis assays in NIH3T3/hematopoietic cells

   PMID:12574163

   Open questions at the time

   • Direct physiological substrates of STRADB kinase activity not identified
   • Why ERK6/p38γ activation requires kinase activity but JNK1 activation does not is unexplained
   • Molecular link between cytoskeletal remodeling and apoptosis resistance not defined
3. 2003 Medium

   Placed STRADB within the LKB1–Mo25 complex and showed it controls LKB1 subcellular localization, implicating it in spatial regulation of LKB1 signaling.

   Evidence Tandem affinity purification with mass spectrometry and LKB1 translocation assays in cultured cells

   PMID:14676191

   Open questions at the time

   • Whether STRADB-driven LKB1 relocalization activates MARK kinases not directly demonstrated
   • How LKB1/Mo25 binding relates to STRADB's XIAP/TAK1 and stress-kinase functions unclear
   • Stoichiometry and architecture of the STRADB–LKB1–Mo25 complex not resolved

• How STRADB integrates its LKB1/Mo25 scaffolding role with its XIAP–TAK1 anti-apoptotic and stress-kinase functions, and the identity of its physiological substrates, remain unresolved.
• No direct kinase substrate identified
• No structural model of the STRADB–LKB1–Mo25 complex
• Whether the LKB1-scaffolding and XIAP/JNK functions occur in the same cells or pathways is unknown